Summit Therapeutics PLC (SMMT)
Healthcare
Biotechnology
13.00 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Summit Therapeutics PLC (SMMT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -168 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -15 | -24 | -26 | -23 | -39 | -47 | -69 | -93 | -76 | -93 | -168 | -429 | |
| 0.0 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.1 | -7.0 | |
| 0.6 | 6.9 | 7.6 | 8.8 | 15 | 8.8 | 8.6 | 97 | 131 | 83 | 55 | 86 | 355 | |
| 3.4 | 6.6 | 3.3 | 2.4 | 6.8 | -0.5 | -4.8 | 5.8 | 7.9 | 6.2 | -1.3 | 4.2 | 17 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 | 1.0 | 1.3 | |
| -2.9 | 48 | 16 | -158 | -83 | 67 | 124 | -0.1 | – | -360 | -0.2 | 223 | – | |
| – | – | – | – | -76 | -25 | – | – | – | 0.0 | – | – | – | |
| 0.2 | 4.9 | 0.4 | 158 | 156 | -19 | 5.9 | 25 | 34 | 426 | 2.9 | 457 | 919 | |
| -15 | 38 | -7.8 | -26 | 50 | 8.9 | 83 | -44 | -59 | -9.9 | -90 | 512 | 352 | |
| -12 | -15 | -24 | -26 | -23 | -39 | -48 | -69 | -93 | -76 | -93 | -169 | -431 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.